EMA Authorised: Enwylma — Zentiva k.s.

View source ↗

Summary

The EMA authorised Enwylma from Zentiva k.s. for neoplasms of bone tissue, including giant cell tumor of bone, with the decision dated 15 April 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Neoplasms
• Giant Cell Tumor of Bone

Drugs mentioned

• Enwylma

Snippet

Status: Authorised. Therapeutic area: Neoplasms, Bone Tissue;Giant Cell Tumor of Bone. MAH: Zentiva k.s.. Decision date: 15/04/2026